VANCOUVER, March 30 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. , a biotechnology company developing drugs in the field of chemokines, today announced its engagement of Elite Financial Communications Group, LLC, a full-service financial communications firm, to manage all aspects of its investor and media relations programs, including extensive communications and outreach to the institutional investment community.
Elite will work closely with Chemokine's executive management team to develop comprehensive corporate messages that will most pro-actively leverage senior management's strategic vision for the Company. In addition, Elite will assist in the development of customized, high-quality, high-impact and fully integrated communications programs designed to increase, maintain and enhance investor and media awareness of the Company's exciting growth strategies.
Dodi Handy, President and CEO of Elite, stated, "Having just raised ample capital to fund its business plan, Chemokine Therapeutics is rapidly advancing through clinical trials of its two lead drug candidates. With a vision to revolutionize the treatment of cancer, among other deadly diseases, Chemokine is a company that is sure to distinguish itself in its industry and on Wall Street. Elite is honored to be working with Chemokine and looks forward to playing a meaningful role in fostering broad awareness and market support for the Company."
About Elite Financial Communications Group, LLC
Headquartered in Lake Mary, Florida, Elite Financial Communications Group combine diverse expertise, influence, talent and capabilities to achieve quantifiable results for both publicly traded and privately held companies. Established in 2001 by a partnership group composed of highly reputable financial, marketing and business experts, Elite is rapidly earning international distinction for challenging industry convention and for taking the lead in establishing best practices for pro-active financial communications, investor relations, media relations and strategic resource services. For more information on Elite, please visit www.efcg.net.
About Chemokine Therapeutics Corp.
Chemokine Therapeutics is a product-focused biotechnology company developing drugs that harness the therapeutic potential of stem cells through chemokine pathways. Chemokines are a class of proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, as well as tissue repair and regeneration. Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation. Chemokine Therapeutics is a leader in research in this field. The Company has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth. For more information, please visit its website at www.chemokine.net.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward- looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
For further information contact: Chemokine Therapeutics Frederica Bell Director, Investor Relations Phone: (604) 827-3131 Email: fbell@chemokine.net Or Elite Financial Communications Group, LLC Dodi Handy, President and CEO Phone: (407) 585-1080 Email: chkt@efcg.net
Chemokine Therapeutics Corp.CONTACT: Chemokine Therapeutics, Frederica Bell, Director, InvestorRelations, Phone: (604) 827-3131, Email: fbell@chemokine.net; Or EliteFinancial Communications Group, LLC, Dodi Handy, President and CEO, Phone:(407) 585-1080, Email: chkt@efcg.net
